Fundraising Fox
Hemispherian
Oslo · Founded 2020 · Norway corporation · 2 known investors
Find your way into Hemispherian
Sign up to see every warm intro you have to Hemispherian
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Hemispherian team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Hemispherian is a clinical-stage pharmaceutical company developing small molecule drugs that target the TET2 enzyme as targeted therapies for aggressive cancers. Its lead compound GLIX1 is entering clinical development for glioblastoma, a cancer of the central nervous system.
Founders & leadership
Hemispherian was founded in 2020 by Terezia Prikrylova, Adam Brian Robertson, and Zeno Albisser.
TP
Terezia PrikrylovaCo-founder · Chief Operating Officer2019–2026Terezia Prikrylova co-founded Hemispherian in Oslo in 2019 and led the development of a TET2-targeting small molecule compound through preclinical and regulatory stages, including securing FDA IND clearance and two Orphan Drug Designations. She holds a PhD in molecular biology and has expertise in preclinical research management, regulatory submissions, and drug development programme governance.
AB
Adam Brian RobertsonCo-founder
ZA
Zeno AlbisserCo-founder · Chief Executive OfficerZeno Albisser founded and leads Hemispherian, a clinical-stage pharmaceutical company developing small molecule drugs targeting the TET2 enzyme for cancer treatment. He previously worked as a software engineer and engineering manager.
Board
AM
Anett Monika DiazBoard director
Investors · 2
Biflisted by BifHamburg
How we know: Bif's portfolio page · Not right? Tell us
InvestinorreportedTrondheim
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$107.7K disclosed across 2 rounds · 2020–2022
▶$50KraisedMay 2022 · 2 investors · PharmaceuticalsRule 506(c)
▶$50KraisedMay 2022 · 2 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Masha Paule Nathalie Legris StrommeDirector
- Dallas Christian HackDirector
- Terezia PrikrylovaPromoter
- Cecilie Stenstadvold SverdrupDirector
- Adam Brian RobertsonPromoter
- Steven John PowellDirector
- Zeno AlbisserExecutive Officer
- Offering amount
- $50K
- Amount sold
- $50K
- Minimum investment
- $10K
- Proceeds to insiders
- $10K
- First sale
- Apr 2022
- Incorporated
- Corporation, Norway, 2020
- Federal exemptions
- 06c, 4a5
▶$57.7KraisedJan 2021 · 2 investors · PharmaceuticalsRule 506(c)
▶$57.7KraisedJan 2021 · 2 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Terezia PrikrylovaDirector
- Adam Brian RobertsonDirector
- Zeno AlbisserExecutive Officer, Director
- Anett Monika DiazDirector
- Offering amount
- $57.7K
- Amount sold
- $57.7K
- Minimum investment
- $20K
- Proceeds to insiders
- $10K
- First sale
- Dec 2020
- Incorporated
- Corporation, Norway, 2020
- Federal exemptions
- 06c, 4a5
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Hemispherian do?
- Hemispherian is a clinical-stage pharmaceutical company developing small molecule drugs that target the TET2 enzyme as targeted therapies for aggressive cancers. Its lead compound GLIX1 is entering clinical development for glioblastoma, a cancer of the central nervous system.
- Who founded Hemispherian?
- Hemispherian was founded by Terezia Prikrylova, Adam Brian Robertson, Zeno Albisser in 2020.
- Who are Hemispherian's investors?
- Hemispherian's investors include Bif, Investinor.
- How much funding has Hemispherian raised?
- Hemispherian has disclosed $107.7K raised across 2 rounds.
- Where is Hemispherian headquartered?
- Hemispherian is headquartered in Oslo.